Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2000	FY 1999	FY 1998	FY 1997
Period Ending	Dec '24 Dec 31, 2024	Sep '00 Sep 30, 2000	Sep '99 Sep 30, 1999	Sep '98 Sep 30, 1998	Sep '97 Sep 30, 1997
Revenue	-	4.08	1.79	2.84	0.01
Revenue Growth (YoY)	-	127.60%	-36.97%	30673.25%	-
Cost of Revenue	-	4.16	1.79	2.49	0
Gross Profit	-	-0.08	-0	0.35	0.01
Selling, General & Admin	0.64	0.25	0.26	0.28	0.03
Operating Expenses	0.64	0.48	0.42	0.41	0.03
Operating Income	-0.64	-0.56	-0.42	-0.06	-0.02
Interest & Investment Income	1.3	-	-	-	-
Currency Exchange Gain (Loss)	-	-	-	-0.01	-0.01
Other Non Operating Income (Expenses)	-0.89	-	-	-	-
EBT Excluding Unusual Items	-0.23	-0.56	-0.42	-0.06	-0.03
Gain (Loss) on Sale of Assets	-	-0.01	0.02	-0.07	-0.17
Pretax Income	-0.23	-0.57	-0.39	-0.13	-0.21
Income Tax Expense	-	-0.15	-0.01	-	-
Net Income	-0.23	-0.43	-0.38	-0.13	-0.21
Net Income to Common	-0.23	-0.43	-0.38	-0.13	-0.21
Shares Outstanding (Basic)	8	21	20	19	17
Shares Outstanding (Diluted)	8	21	20	19	17
Shares Change (YoY)	-60.56%	2.19%	9.69%	11.11%	-
EPS (Basic)	-	-0.02	-0.02	-0.01	-0.01
EPS (Diluted)	-	-0.02	-0.02	-0.01	-0.01
Free Cash Flow	-0.23	-0.05	-0.44	-0.19	-0.24
Free Cash Flow Per Share	-0.03	-0.00	-0.02	-0.01	-0.01
Gross Margin	-	-2.05%	-0.06%	12.47%	85.13%
Operating Margin	-	-13.81%	-23.24%	-1.94%	-264.81%
Profit Margin	-	-10.48%	-21.22%	-4.70%	-2222.65%
Free Cash Flow Margin	-	-1.11%	-24.65%	-6.65%	-2603.83%
EBITDA	-	-0.33	-0.26	0.08	-0.02
EBITDA Margin	-	-8.06%	-14.60%	2.71%	-260.53%
D&A For EBITDA	-	0.23	0.15	0.13	0
EBIT	-0.64	-0.56	-0.42	-0.06	-0.02
EBIT Margin	-	-13.81%	-23.24%	-1.94%	-264.82%

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q